Skip to content
← Full study record

NCT03860844 · MORE INFO

Limitations, agreements, and source contact

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia · Source last updated 2025-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns.
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi aventis recherche & développement
phone
800-633-1610
phone Ext
6#
title
Trial Transparency Team
Complete source fields
certain Agreement
other Details
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns.
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi aventis recherche & développement
phone
800-633-1610
phone Ext
6#
title
Trial Transparency Team

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice